Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Generic interferon-beta
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Therapeutic Testosterone Administration Preserves Excitatory Synaptic Transmission in the Hippocampus during Autoimmune Demyelinating Disease.
Early signs of memory impairment among multiple sclerosis patients with clinically isolated syndrome.
Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects.
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Effect of Genzyme’s LEMTRADA™ maintained in patients beyond two-year pivotal MS studies
New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients
Generic Midamor
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Ono to enter license agreements with Merck KGaA
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.

Pages